445.43

1.79% -8.10

After Hours: 445.43

United Therapeutics Corp (UTHR)

Overview News Price History Option Chain Financials Why UTHR Down? Discussions Forecast Stock Split

United Therapeutics Corp stock is traded at $445.43, with a volume of 725.89K. It is down -1.79% in the last 24 hours and up +6.25% over the past month. United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Previous Close:

$453.53

Open:

$451.6

24h Volume:

725.89K

Relative Volume:

0.92

Market Cap:

$20.09B

Revenue:

$3.08B

Net Income/Loss:

$1.24B

P/E Ratio:

17.39

EPS:

25.6108

Net Cash Flow:

$1.07B

1W Performance:

+6.41%

1M Performance:

+6.25%

6M Performance:

+46.96%

1Y Performance:

+19.11%

1-Day Range:

$440.50

$452.52

1-Week Range:

$409.07

$479.50

52-Week Range:

$266.98

$479.50

United Therapeutics Corp Stock (UTHR) Company Profile

Name

United Therapeutics Corp

Sector

Healthcare (1135)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

(301) 608-9292

Address

1000 SPRING ST, SILVER SPRING, MD

Employee

1,305

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

UTHR's Discussions on Twitter

Compare UTHR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
UTHR United Therapeutics Corp	445.43	19.53B	3.08B	1.24B	1.07B	25.61
ZTS Zoetis Inc	144.09	63.86B	9.39B	2.62B	2.22B	5.8121
TAK Takeda Pharmaceutical Co Adr	13.44	41.80B	29.96B	957.25M	4.77B	0.2956
HLN Haleon Plc Adr	9.27	40.88B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	20.48	22.98B	16.70B	-157.13M	1.19B	-0.1446

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Initiated	Wells Fargo	Underweight
Sep-26-25	Initiated	RBC Capital Mkts	Outperform
Jun-02-25	Initiated	Cantor Fitzgerald	Overweight
Apr-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-21-25	Upgrade	BofA Securities	Underperform → Neutral
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-12-24	Upgrade	Goldman	Sell → Neutral
Feb-05-24	Initiated	Leerink Partners	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Dec-06-22	Initiated	UBS	Buy
Dec-05-22	Initiated	Goldman	Sell
Oct-11-22	Initiated	Morgan Stanley	Overweight
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jun-25-20	Reiterated	H.C. Wainwright	Neutral
Mar-10-20	Upgrade	Jefferies	Hold → Buy
Feb-27-20	Upgrade	Cowen	Market Perform → Outperform
Jan-31-20	Upgrade	JP Morgan	Neutral → Overweight
Dec-03-19	Initiated	BofA/Merrill	Underperform
Aug-01-19	Upgrade	Jefferies	Underperform → Hold
Aug-01-19	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jul-01-19	Upgrade	Credit Suisse	Neutral → Outperform
May-17-19	Upgrade	UBS	Sell → Neutral
May-09-19	Upgrade	Credit Suisse	Underperform → Neutral
Oct-12-18	Upgrade	Standpoint Research	Hold → Buy
Aug-08-18	Downgrade	Credit Suisse	Neutral → Underperform
Apr-03-18	Upgrade	Credit Suisse	Underperform → Neutral
Feb-22-18	Reiterated	Barclays	Underweight
Jan-18-18	Resumed	Credit Suisse	Underperform
Dec-27-17	Reiterated	Wedbush	Outperform
Apr-27-17	Reiterated	Wedbush	Outperform
Mar-30-17	Initiated	UBS	Sell
Mar-16-17	Initiated	Credit Suisse	Underperform

View All

United Therapeutics Corp Stock (UTHR) Latest News

Nov 01, 2025

United Therapeutics Hits Day High with 9.63% Surge in Stock Price - Markets Mojo

Nov 01, 2025

Is United Therapeutics Corporation (UTH) stock a top dividend aristocrat candidateRisk Management & Reliable Entry Point Trade Alerts - newser.com

Nov 01, 2025

United Therapeutics Corp. Hits New 52-Week High of $479.50 - Markets Mojo

Nov 01, 2025

Focus Partners Advisor Solutions LLC Buys Shares of 1,440 United Therapeutics Corporation $UTHR - MarketBeat

Nov 01, 2025

Oct 31, 2025

United Therapeutics Corp’s Earnings Call Highlights Growth and Innovation - MSN

Oct 31, 2025

Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat

Oct 31, 2025

3rd Circ. Preview: BMW, MiLB And Sandoz Top Nov. Lineup - Law360

Oct 31, 2025

United Therapeutics (NASDAQ:UTHR) Given New $423.00 Price Target at Wells Fargo & Company - MarketBeat

Oct 31, 2025

Assetmark Inc. Boosts Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat

Oct 31, 2025

Will United Therapeutics Corporation stock benefit from upcoming earnings reportsOptions Play & Technical Pattern Alert System - newser.com

Oct 31, 2025

Oct 30, 2025